Clinical pharmacology of anti-il-17 receptor antibody khk4827 (brodalumab) in Japanese healthy volunteers and subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

被引：0
|
作者：
Nemoto, O. [1 ]
Nagashima, H. [2 ]
Sayama, K. [3 ]
Kobayashi, H. [4 ]
机构：
[1] Sapporo Skin Clin, Sapporo, Hokkaido, Japan
[2] Yanagibashi Hosp, Yanagibashi Clin Trial Ctr, Tokyo, Japan
[3] Ehime Univ, Grad Sch Med, Dept Dermatol, Matsuyama, Ehime 790, Japan
[4] Med Corp Shinanokai, Shinanozaka Clin, Tokyo, Japan
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P049
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF SUBCUTANEOUS BRODALUMAB, A FULLY HUMAN ANTI-IL-17RA MONOCLONAL ANTIBODY, FOR SYSTEMIC SCLEROSIS WITH MODERATE-TO-SEVERE SKIN THICKENING: A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 3 STUDY
    Fukasawa, T.
    Yoshizaki, A.
    Kagebayashi, H.
    Sato, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 736 - 737
  • [32] Tolerability and Pharmacokinetics of Avanafil, a Phosphodiesterase Type 5 Inhibitor: A Single- and Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study in Healthy Korean Male Volunteers
    Jung, Jinah
    Choi, Sangmin
    Cho, Sang Heon
    Ghim, Jong-Lyul
    Hwang, Aekyung
    Kim, Unjib
    Kim, Bong Sik
    Koguchi, Atsushi
    Miyoshi, Shinji
    Okabe, Hirotaka
    Bae, Kyun-Seop
    Lim, Hyeong-Seok
    CLINICAL THERAPEUTICS, 2010, 32 (06) : 1178 - 1187
  • [33] Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study
    Miyoshi, Izuru
    Fujimoto, Yoko
    Yamada, Masahito
    Abe, Sadahiro
    Zhao, Qinying
    Cronenberger, Carol
    Togo, Kanae
    Ishibashi, Taro
    Bednar, Martin M.
    Kupiec, James W.
    Binneman, Brendon
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (12) : 911 - 923
  • [34] Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid x receptor (FXR)-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase? study
    Xu, Jia
    Zhang, Hong
    Chen, Hong
    Zhu, Xiaoxue
    Xu, Zhong-Nan
    Huo, Dandan
    Jia, Haiyan
    Ding, Yanhua
    Niu, Junqi
    JOURNAL OF HEPATOLOGY, 2020, 73 : S466 - S466
  • [35] First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers
    Blank, Antje
    Hohmann, Nicolas
    Dettmer, Marlen
    Manka-Stuhlik, Anette
    Mikus, Gerd
    Stoll, Felicitas
    Stuetzle-Schnetz, Marlies
    Thomas, Daniel
    Exner, Evelyn
    Schmitt-Bormann, Beate
    Schaller, Torsten
    Laage, Rico
    Schoenborn-Kellenberger, Oliver
    Arndt, Michaela
    Haefeli, Walter E.
    Krauss, Juergen
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (10): : 2366 - 2377
  • [36] A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
    Papp, K.
    Pariser, D.
    Catlin, M.
    Wierz, G.
    Ball, G.
    Akinlade, B.
    Zeiher, B.
    Krueger, J. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (03) : 767 - 776
  • [37] Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study
    Dai, Zhijie
    Fang, Pingfei
    Yan, Xiang
    Zhu, Ronghua
    Feng, Qiong
    Yan, Qiangyong
    Yang, Lingfeng
    Fan, Xiao
    Xie, Yuting
    Zhuang, Lihong
    Feng, Sheng
    Liu, Yantao
    Zhong, Sheng
    Yang, Zeyu
    Sheng, Zhifeng
    Zhou, Zhiguang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [38] Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial
    Choy, EHS
    Isenberg, DA
    Garrood, T
    Farrow, S
    Ioannou, Y
    Bird, H
    Cheung, N
    Williams, B
    Hazleman, B
    Price, R
    Yoshizaki, K
    Nishimoto, N
    Kishimoto, T
    Panayi, GS
    ARTHRITIS AND RHEUMATISM, 2002, 46 (12): : 3143 - 3150
  • [39] Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study
    Xu, Jia
    Zhang, Hong
    Chen, Hong
    Zhu, Xiaoxue
    Jia, Haiyan
    Xu, Zhongnan
    Huo, Dandan
    Zhang, Hong
    Li, Cuiyun
    Ding, Yanhua
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [40] Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Ra Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
    Wynne, Christopher John
    Cole, Alexandra
    Lemech, Charlotte
    Wang, Guoqin
    Zhang, Yu
    Chen, Benchao
    Wang, Max
    Li, Baiyong
    Xia, Michelle
    Sinclair, Rodney
    DERMATOLOGY AND THERAPY, 2023, 13 (10) : 2357 - 2373
12345